Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Hussain M, Quinn D, Dorff T, Lerner S, Thompson I, Agarwal N. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2437871. PMID: 39374015, DOI: 10.1001/jamanetworkopen.2024.37871.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerMetastatic castration-resistant prostate cancerCirculating tumor cell countCirculating tumor cellsHormone-sensitive prostate cancerTumor cell countOverall survivalProstate cancerPrognostic valueCTC countsPrognostic factorsProgression to metastatic castration-resistant prostate cancerDiagnosed mHSPCPeripheral blood circulating tumor cellsClinical trialsBlood circulating tumor cellsCastration-resistant prostate cancerPrognostic studyCell countBaseline CTC countProgression-free survivalLines of therapyEnhanced overall survivalProstate-specific antigenIncreased prognostic valueSWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC).
Maughan B, Plets M, Pal S, Ged Y, Tangen C, Vaishampayan U, Lerner S, Thompson I. SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC). Journal Of Clinical Oncology 2024, 42: tps493-tps493. DOI: 10.1200/jco.2024.42.4_suppl.tps493.Peer-Reviewed Original ResearchPapillary renal cell carcinomaProgression free survivalMedian progression free survivalImmune therapyAdvanced papillary renal cell carcinomaComparison of progression free survivalClinical trialsPhase II randomized trialObjective response rateLines of therapyPresence of metastasesRenal cell carcinomaSignificant autoimmune diseaseSingle arm trialRandomized clinical trialsStandard of careAdjuvant pembrolizumabFree survivalMetastatic diseaseOverall survivalCell carcinomaPrimary endpointPathological confirmationSecondary endpointsTargeted therapy